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Abstract

This critical review examines in vitro and in vivo evidence for the influence of
engineered nanomaterial (ENM) physicochemical properties on their distribution into,
and effects on, the nervous system. Nervous system applications of ENMs; exposure
routes and potential for uptake; the nervous system and its barriers to ENM uptake; and
the mechanisms of uptake into the nervous system and overcoming those barriers are
summarized. The findings of English-language publications of studies that included at
least two variations of an ENM physicochemical property and reported results of their
pharmacokinetic and/or pharmacodynamic interaction with the nervous system that
differed as a function of ENM physicochemical property(ies) are summarized in the
Supporting Materials. A summary conclusion is drawn for each of the physicochemical
properties on the strength of the evidence that it influences ENM-nervous system
interaction.

Keywords
Chemical composition; shape; size; surface charge; surface coating

Abbreviations
BBB
BMEC
CNS
ENM
NS

blood-brain barrier
brain microvascular (capillary) endothelial cell
central nervous system
engineered nanomaterial
nervous system
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I. Nervous system applications of engineered nanomaterials (ENMs)
There are reviews of the impact of the physicochemical nature of engineered
nanomaterials (ENMs) on biological systems 1; their circulation, biodistribution, cellular
internalization, and trafficking 2; the contribution of the biological corona to their effects
3

; and their impact on biological activity related to the brain and retinal diseases 4.

However, there has not been a critical review of the significance of the physicochemical
properties of ENMs on the distribution into, and effect on, the nervous system (NS). This
review addresses that information gap. It focuses on the influence of ENM
physicochemical properties on their distribution/translocation to the NS and resultant
effects. There is extensive interest in ENM use as drug and diagnostic agent delivery
systems to the NS for pharmaco- and thermotherapy, as contrast agents for MRI
visualization, as photosensitizers for diagnosis, and for cell labeling and cell
replacement (e.g., for neurodegenerative disorders), including labeling mesenchymal
stem cells to follow their fate. Much of the work has focused on cancer 5 and much
research has investigated polymer-based ENMs. Most of the ENMs that have been
studied are first generation, passive nanostructures, and second generation ENMs
(active, such as targeted drugs). Third generation ENMs (nanosystems) such as neuroelectronic interfaces and fourth generation ENMs (molecular nanosystems), have not
yet been studied in the NS.
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II. ENM exposure routes and their potential to result in nervous system uptake
Due to the low bioavailability from inhalation, oral, and dermal exposure (below), ENM
administration to achieve a medical goal usually requires systemic or local
administration. Inhalation is the route of greatest concern for unintentional ENM
exposure and uptake, most often from the lungs into systemic circulation and then to the
NS from the blood. ENM translocation from the lungs to systemic circulation is < 5%,
and to the NS very much less 6, 7. Translocation from the lung to the brain after
inhalation of 15 or 80 nm 192iridium was 0.003 and 0.0003%, and for 12, 29, or 213 nm
ceria was 0.01 to 0.4% of the dose 8, 9, whereas brain had 0.0001% of a 7 nm ceria after
its intratracheal instillation 10. Another route of uptake from inhalation exposure is via
sensory nerve endings embedded in airway epithelia in the roof of the nasal cavity (the
olfactory nerve and maxillary branch of the trigeminal nerve), followed by axonal
translocation in unmyelinated neurons (fila olfactoria, which have a diameter of ~100 to
330 nm) to ganglionic and central nervous system (CNS) structures 11. Uptake directly
into the brain by this route bypasses systemic circulation and first pass intestinal and
hepatic metabolism. Drug administration into the nasal cavity is quite easy to achieve. It
is most amenable to potent agents. However, there are concerns about nasal cavity
mucosal irritation, damage, and alteration of olfaction 12. Numerous transporters are
expressed by the olfactory and trigeminal cranial nerves that have terminations in the
nasal epithelium, which might inhibit or facilitate ENM uptake 13, 14. The olfactory nerve
has been demonstrated to mediate uptake of viruses (30 nm polio 15) and some ENMs
(50 nm silver-coated gold colloid 16; 36 nm 13C 17; 30 nm manganese oxide 18; and 95
nm quantum dot loaded particles 19). Other examples are in Tables S3 and S4. This
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uptake appears to be mediated by endocytotic uptake into the neurons (rather than via
transporters), retrograde axonal transport once they enter these sensory neurons, and
interneuron translocation into the brain 20.

Non-inhalation routes of ENM uptake include the oral and dermal routes. Uptake into
the brain after oral/gastric administration of 1 to 200 nm gold, 25 and 80 nm titania, and
7 and 30 nm ceria ENMs was ≤ 0.002% of the dose 10, 21-25. Although ENMs have been
shown to penetrate into skin, most studies have not shown transdermal penetration
through intact skin. Disrupting this barrier with organics, abrasion, or flexing may enable
ENM absorption into the hypodermis to reach blood and lymph vessels 26, 27. It has been
suggested that retrograde transport from nerve endings in the skin could take up ENMs
into the dorsal root ganglia, although it does not appear that this has been
demonstrated 28. The only report suggesting translocation to the NS of ENMs applied
topically was an increase of titanium in brain after application of Degussa P25, but not a
10, 25 or 60 nm titania, to the interscapular skin of hairless mice for 60 consecutive
days 29. Intradermal injection of quantum dots, bypassing the formidable barrier
provided by the stratum corneum, resulted in translocation to the liver, lymph nodes,
and kidney, but not the brain 30.

Intraperitoneal injection of scrapie virus (~25 nm) was thought to result in its uptake by
sympathetic fibers into the NS by retrograde axonal transport. Prions (~10 nm) are
thought to translocate in both directions between the periphery and the NS 31, 32. These
observations suggest ENMs might be similarly taken up. Daily intraperitoneal injection
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of 5 nm anatase titania resulted in more titanium in the brain and greater effects than a
comparable dose of bulk titania. Given the insolubility of titania ENMs, these results
might indicate brain uptake, but verification of titania ENM in brain extravascular space
was not reported 33. Intraperitoneal injection of nanoscale aluminum, copper, gold, and
silver increased levels of these metals in the brain. Changes in brain function were
reported after intraperitoneal injection of these metal ENMs as well as after IL-13-coated
liposomes (Tables S3 and S4), suggesting uptake from the peritoneal cavity. They may
have been taken up directly to the brain via neuronal input or through the recently
described lymphatic system of the brain 34, given the uptake of ENMs by the lymphatic
system 35. The presence of some 500 nm fluorescent latex particles in the brain after
intramuscular injection to mice was attributed to their uptake and translocate by the
lymphatic system 36.

Intravenous injection avoids the above barriers, providing 100% bioavailability. This
route has been extensively investigated for ENM drug delivery and visualization. It is the
best route to determine the potential for ENM entry into the brain’s vasculature and
parenchyma, and resultant effects.

III. The nervous system and its barriers to ENM uptake – The blood-brain barrier,
blood-cerebrospinal fluid barrier, blood-spinal cord barrier, blood-retinal
barrier, and blood-nerve barrier
The NS has two anatomical divisions, the CNS comprised of the brain and spinal cord,
and the peripheral NS comprised of 12 pairs of cranial and 31 pairs of spinal nerves that
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connect the CNS to organs, muscles and glands. The somatic NS includes afferent
neurons that convey information from sensory organs to the brain, primarily to the
cerebral cortex, and includes the olfactory nerve and maxillary branch of the trigeminal
nerve mentioned above. Afferent neurons pass through the spinal nerve dorsal root
ganglia, comprised of neuronal cell bodies that lie along the back of the vertebral
column (spine). Dorsal root ganglia cells and rat PC12 cells are often used as models of
neurons, as frequently cited in the Supporting Materials. The motor component of the
somatic NS conveys efferent messages from the cerebral cortex via neurons to the
skeletal muscles to enable voluntary movements. The autonomic nervous system
afferent component conveys sensory impulses from the blood vessels and internal
organs to brain regions, including the medulla, pons, and hypothalamus that elicit reflex
responses through efferent autonomic nerves to the heart, blood vessels, and all the
body’s organs. The autonomic nervous system has two major components, the
sympathetic and the parasympathetic systems, that often have opposite effects on end
organs, such as the heart, thereby maintaining homeostasis. The healthy brain has
neurons and glial cells (astrocytes, oligodendrocytes, and microglia). The nervous
system has neurons and Schwann cells. The latter, like oligodendrocytes in the CNS,
wrap neuronal axons in a myelin sheath.

Barriers for a material to reach an intracellular target in the NS include the blood-brain,
blood-cerebrospinal fluid, blood-spinal, blood-retinal, and blood-nerve barriers, followed
by the cell’s plasma membrane, and then, depending on the target, perhaps an
organelle membrane such as the nuclear envelope. To reach an intracellular target, a

7

multi-functional nanoconstruct, sequentially presenting different surface properties, may
be required.

The anatomical basis of the blood-brain barrier (BBB) includes the brain microvascular
(capillary) endothelial cells (BMECs) that line the ~5 to 10 µm diameter vessels that
perfuse the brain. Adjoining cells have tight junctions, maintained by several proteins.
The lack of 1 to 1.2 nm lanthanum flux through BBB endothelial cell tight junctions
attests to this barrier’s integrity 37. ENMs are likely to pass through the endothelial cell
membrane (transcellular) rather than between endothelial cells (pericellular) unless this
space is enlarged. Serum proteins penetrated leaky cerebral vessels supplying blood to
the subarachnoid space and pial surface as well as circumventricular organs (which
lack a BBB so they can chemically communicate with blood) 38, suggesting the
penetration of lipid ENMs into the brain through circumventricular organs is possible 39.
However, we did not see nanoceria in the median eminence or pituitary gland, which
lack a BBB 40, 41.

The luminal surface of the BBB is coated with a carbohydrate rich glycocalyx layer
bound to the endothelial cells by glycoproteins and proteoglycans, which contain sialic
acid moieties. This provides a negative charge that is important to maintain BBB
integrity and function. Cations that neutralize this charge can increase BBB permeability
42

. Heparan sulfate containing proteoglycans which constitute ~50 to 90 of the

proteoglycans, such as the extracellular matrix proteoglycan perlecan and the
transmembrane syndecan family, help to maintain and protect the BBB. These

8

proteoglycans can immobilize molecules, such as lipoproteins and chemokines, and
HIV-1, and can mediate cellular uptake of apolipoprotein E (apoE)-containing
lipoproteins and an apoE mimetic peptide Angiopep.

In addition to the barriers to ENM flux across the BBB presented by its physical
components, the BBB expresses many components that protect it and the brain
metabolically and enzymatically. The BMECs have numerous carrier-mediated influx
and efflux transporters, including P-glycoprotein, multidrug resistance protein, and
breast cancer resistance protein that transport lipophilic and other agents out of the
BMECs into blood 43. Most substrates of these transporters are small molecules. The
BMECs also express enzymes, including monoamine oxidase, DOPA decarboxylase,
cholinesterases, GABA transaminases, aminopeptidase, and endopeptidases, that
metabolize neurotransmitters and many xenobiotics. A few cytochrome P 450 drugmetabolizing phase 1 enzymes, CYP1B1 (that metabolizes flavonoids and estradiol)
and CYP2U1 (that metabolizes arachidonic acid, docosahexaenoic acid, and other long
chain fatty acids), and some phase 2 enzymes, GSTP1, COMT, GSTM3, GSTO1 and
GSTM2, are expressed 44. Superoxide dismutase attenuates ROS-induced BBB
disruption, protecting the brain from injury produced by ischemia, methamphetamine,
and other insults 45, 46. Further description can be found in 47-50.

The kinetics of ENM penetration of the blood-brain and blood-retinal barriers has been
described in studies using methods that confirm distribution across the membranes,
including imaging of ENMs in NS cells and use of the capillary depletion method that
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separates brain parenchyma from brain endothelial cells. MWCNTs were seen in the
parenchymal fraction 5 minutes after their intravenous administration 51. One %
polysorbate-coated PBCA and cationic-albumin PEG-poly(ε-caprolactone) ENMs were
seen in the brain parenchymal fraction 30 minutes after their intravenous injection 52, 53.
Using in vivo multiphoton imaging of mice with a cranial window, stained nuclei were
seen beginning 30 min after intravenous injection of nuclear stain-PS80 coated-PBCA
ENM, amyloid plaque staining was seen beginning 15 minutes after intravenous
injection PBCA-ENM coated with Alexa-488–conjugated anti-Aβ antibody, and PBCAENM loaded with a Trypan blue showed a time constant of brain entry of 18 minutes,
corresponding to the BBB crossing time 54. Imaging of rhodamine-labelled PBCA in
retina showed blood-retinal barrier crossing in 20 to 25 minutes 55. In the only found
study of metal-based ENMs that showed short-term NS entry, transferrin-conjugated
fluorescein-loaded Fe3O4 nanoparticles were seen 1 hour after their intravenous
injection into rats, the only time studied 56.

IV. The mechanisms of substance uptake into the NS and overcoming barriers to
ENM uptake
The mechanisms of substance uptake into cells include diffusion (adsorptive
transcytosis), carrier-mediated transport, and receptor-mediated processes 57. The
receptor-mediated processes include facilitated diffusion, active transport, and
endocytosis (the engulfing of particles and uptake in small vesicles into a cell) 58.
Diffusion across the BBB favors molecules < 500 Da (~1 nm) and lipophilic substances
59, 60

. Endocytotic processes are believed to be the major mechanism of ENM cell
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uptake 61. Endocytotic processes involve phagocytosis and pinocytosis
(macropinocytosis, caveolae, clathrin-coated pits, and clathrin- and caveolaeindependent uptake). Phagocytosis can engulf spherical particles from ~200 to 3000 nm
into a vacuole. Caveolar uptake occurs in non-fenestrated endothelial cells, involving an
invagination of the cell membrane surrounded by the protein caveolin on the
cytoplasmic surface, receptor proteins, and invagination into the cell. The caveolaemediated uptake pit diameter is ~50 to 80 nm. Although endothelial cells in the
mammalian brain have fewer pinocytotic vesicles than most other tissues 62, this route
was shown to mediate uptake of neutral and cationic ENMs across a co-culture of
bovine brain microvascular endothelial cells and mixed glial cells 63. The clathrin coatedand clathrin/caveoli-independent pit diameters are ~120 and ~90 nm, respectively.
However, one should not think that these diameters limit the size of ENMs that can be
taken up by these processes 64.

Several approaches to enhance brain ENM uptake have been investigated; molecular
Trojan horse approaches to enable hitchhiking through the BBB. These include surface
functionalization/conjugation to transferrin (to be recognized by the transferrin receptor
subtype-1 for receptor-mediated endocytosis), transferrin receptor antibodies, lactoferrin
(to be recognized by the lactoferrin receptor for receptor-mediated endocytosis),
apolipoprotein E (apoE) and the peptide Angiopep (an apoE-mimetic peptide ligand)
that are recognized by the low density lipoprotein receptor, insulin-like growth factor
binding protein (for recognition by the insulin-like growth factor receptor), and a rabies
virus-derived peptide 65-67. The BBB can be intentionally compromised to enhance
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distribution into the CNS. Focused ultrasound that creates microbubbles has been
shown to open targeted BBB regions for a few hours to enhance local brain uptake 68,
and has been used to transiently increase BBB permeability to enhance brain gold ENM
delivery as well as doxorubicin and gadolinium in polymers 69-72. The BBB tight junctions
can be temporarily opened by intra-carotid infusion of hyper-osmotic (~25%) mannitol,
which has been used for brain cancer chemotherapy 73. No reports were found that
investigated the interaction of physicochemically-different ENMs with the brain when
these methods were used to open the BBB.

V. Addressing the knowledge base of this review
This review is based on English-language publications of ENM studies which had at
least 2 variations of a physicochemical property that resulted in different ENM
interaction (pharmacokinetic and/or pharmacodynamic) with the NS or its components.
The physicochemical properties of both the synthetic identity (the ENM as made) and
the bioidentity (biological identity, transformed from the synthetic identity by protein
coating, aging, etc.) were considered. It is assumed that the response to a transformed
ENM will not be the same as to its synthetic identity 74. For example, aging (oxidation) of
zero valent iron decreased its toxicity 75 and MWCNT oxidation altered cell response
and ENM distribution and degradation 76-78. Publications were reviewed for results
related to five ENM physicochemical properties (chemical composition, size, shape,
surface charge, and surface coating). For in vitro studies, reports were reviewed for
comparative results of the five physicochemical properties on eleven NS cell types (or
mixtures thereof); stem, blood-brain barrier, blood-peripheral nerve barrier, blood-retinal
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barrier, microglia, astrocytes, oligodendroglia, neural, peripheral NS cells, mixtures of
NS cells, and tumor cells. For in vivo studies, reports were reviewed for comparative
results of the five physicochemical properties studied in healthy vs. disease model
animals.

The strategy to identify the literature examined for this review included PubMed, Web of
Science, and SciFinder searches, followed by searches and examination of references
cited by the identified reports and reviews. Five PubMed database searches were
conducted between November 2012 and January 2016. The cumulative yield of 1344
English-language citations produced ~ 550 unique citations. The PubMed search
strategy used a combination of relevant controlled vocabulary terms from Medical
Subject Headings [Mesh] and Text Words (words or phrases found in either an article
title or abstract). Core anatomic and disease MeSH terms included Nervous System
OR Nervous System Diseases, which yields more specific terms indexed below the
main terms in the PubMed tree structure. To increase initial yield, text words were also
searched, including Neuro* OR Nerv* OR Brain OR Astrocyte* OR Retinal OR
Microglia* OR Apoptosis OR Cerebrospin* OR Mening* OR Encephal* OR Alzheimer*
OR Parkinson* OR Dementia. Asterisks (*) were used to force truncation and find
variable endings to root terms. Nanotoxicology search criteria primarily relied on
"Nanostructures"[Mesh], plus text words. Core terms included Nanotox* OR Nanotech*
OR Namomolec* OR Nanomaterial* OR Nanotech* OR Nanoparticl* OR Nanodot* OR
Nanotub* OR Biotransform* OR Ultra fine OR Quantum Dot. Additionally, Title Word
searches for terms such as Genotox* OR Cytotox* OR Neurotox* OR Toxic* were used,
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then combined with the neurotoxicology search terms. Additionally, the PubMed “Similar
Articles” algorithm was used for articles that appeared to be of high relevance.

The PubMed keywords were used to devise the Web of Science search strategy. Three
separate searches were conducted during the same timeframe as the PubMed
searches. The strategy was filtered, focusing on title words and research design. This
returned 325 citations.

Ten targeted SciFinder searches were conducted in October, 2015 to look for
publications to fill in ENM physicochemical property pharmacokinetic and/or
pharmacodynamic interaction cells lacking entries. Search terms were: stem cells nano
nervous system, blood-peripheral nerve barrier nano, peripheral nerve barrier nano,
peripheral nerve nanomaterial, peripheral nerve nano, blood-retinal barrier nano, bloodnerve barrier nano, oligodendroglia nano, astrocyte nano, and astrocyte nanoparticle
nanomaterial.

The author read the abstract of all returned citations to select the reports that appeared
to report studies that included at least two variations of an ENM physicochemical
property. Those reports were read to extract the relevant details, resulting in the ~ 235
reports summarized in the Supporting Materials and > 230 reports that did not include at
least two variations of an ENM physicochemical property that resulted in ENM
physicochemical property-dependent different responses.
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Introduction to Sections VI to IX
Summaries of the influence of the physicochemical properties of ENMs on their
interaction with the NS, organized according to the five physicochemical properties and
study material (in vitro by cell type or in vivo) have been summarized in 4 tables in the
Supporting Materials. Tables S1 and S2 report in vitro results, Tables S3 and S4 report
in vivo results. Tables S1 and S3 contain summaries of reports of studies that
determined pharmacokinetic endpoints, and Tables S2 and S4 contain summaries of
reports of studies that determined pharmacodynamic (effect) results. Tables S1 and S2
include the eleven cell types searched. Tables S3 and S4 distinguish between studies
conducted in healthy vs. disease model animals, noting the NS region or cell type
studied, animal species, and route of ENM administration. Entries under a
physicochemical property and study material are chronological; the oldest listed first.
The absence of an entry under a physicochemical property for a cell type (Tables S1
and S2) or animal status (Tables S3 and S4) indicates no information was found.

The level of evidence that a differentiating ENM physicochemical property influences
NS interaction, based on the reports summarized in Tables S1 to S4, is presented in
Tables 1 to 4. An entry of No indicates no evidence. N/S indicates the evidence is not
strong, often because only one report addressed this condition. An entry of S indicates
strong evidence, based on more than one well-conducted and interpreted study and/or
multiple supporting studies in the absence of multiple studies with conflicting results. For
many studies, it is difficult to attribute a different response to two or more ENMs to a
single physicochemical property because the structural/chemical difference(s) among
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the ENMs represent more than one physicochemical property, the entanglement of their
physicochemical properties 79. This is particularly relevant when trying to attribute a
difference to surface charge which is often confounded by the functional groups that
provide the different charges. For N/S and S entries, reports that provide the strongest
evidence are cited.

VI. In vitro studies reporting the influence of ENM physicochemical properties on
their pharmacokinetic responses (uptake, distribution, and persistence)
Table 1 indicates the level of evidence (based on studies summarized in Table S1) that
each of the five physicochemical properties has on the pharmacokinetics of ENM cell
type/cell mixture interaction. Only 4 reports with stem cells, 1 with oligodendrocytes, and
4 with normal astrocytes studied alone were found, preventing very many conclusions
that physicochemical properties influence ENM pharmacokinetic interaction with these
cells. Although ENMs have been studied as scaffolds for regeneration of peripheral
nerve cells, no reports were found of ENM pharmacokinetic interaction with peripheral
NS cells (other than dorsal route ganglia cells that are included with neurons) or the
blood-nerve barrier, accounting for the absence of entries for these targets in Table 1.
Some conclusions can be drawn from the studies cited in Table 1. More than half of the
studies summarized in Table S1 were of BBB models. Of these, nine used hCMEC/D3
cells. Reports using these human-derived cells were given more credence than reports
using other cells when summarizing the strength of evidence in Table 1. The literature
consistently shows an inverse relationship between ENM size and extent of distribution
across in vitro models of the BBB. Results with tumor-derived cells suggest greater cell
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association or uptake of 40 to 50 nm ENMs than larger or smaller ones, consistent with
the conclusion that ~ 50 nm in the optimum size for uptake by non-phagocytic
eukaryotic cells 80. There is insufficient information to know if this is true for non-tumor
NS cells. Permeation through the BBB appears to be favored for ENMs with closer to,
or with, neutral surface charge. Cell membrane surfaces, including brain
microvasculature endothelial cells, are negatively charged, so ENMs with a net negative
surface potential would be expected to have difficulty approaching the cell membrane.
However, this is not consistent with the conclusion that increasing surface charge, either
positive or negative, favors particle uptake by non-phagocytic eukaryotic cells 80. The
evidence that surface coating influences the pharmacokinetics of ENMs on NS cells
comes from the many studies that investigated methods to deliver ENMs across the
BBB to the brain, and some studies that assessed the risk of brain parenchyma ENM
entry. Two of the four studies that compared non-tumor- and tumor-derived cells show
different response, suggesting more work is warranted to selectively target ENMs to NS
tumor cells.

VII.

In vitro studies describing the influence of ENM physicochemical

properties on their pharmacodynamic responses (effects/responses of the cell
type)
Table 2 indicates the level of evidence (based on studies summarized in Table S2) that
each of the five physicochemical properties has on the effects produced by ENMs on
NS cell types or cell mixtures. As with pharmacokinetic endpoints, the lack of sufficient
studies (none were found for blood-peripheral nerve barrier or peripheral cells, only one
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was found for the blood-retinal barrier and for oligodendrocytes, and three with normal
astrocytes studied alone) prevents conclusions of the influence of physicochemical
properties on the effects of ENMs on these barriers and cells. Generally, from a few to a
few hundred nm, effects on cells decreased as size increased. This trend was seen with
stem, blood-brain barrier (which represented < 20% of the entries in Table S2), neuronal
(which represented 35% of the entries in Table S2), and tumor cells. Only 1 study
compared surface coating in non-tumor and tumor cells 81, providing insufficient
information to conclude if they respond similarly.

VIII.

In vivo studies reporting effects of the influence of ENM physicochemical

properties on their pharmacokinetic responses (uptake, distribution, and
persistence)
Table S3 contains summaries of reports of studies that determined pharmacokinetic
endpoints in the NS of the mouse, rat, and rabbit (1 study) of more than one ENM.
There are many reports concluding that ENMs enter the brain. For ENMs from < 2 to
500 nm, there was generally an inverse relationship between size and brain association
after intravenous administration; supported by studies cited in Table 3. For most studies
concluding that ENMs enter the brain, the methods employed were not able to
determine ENM distribution into brain parenchyma. Most studies used methods that do
not account for the ENM in the blood within the vasculature of the brain. Blood occupies
~2% of brain volume in the cortex and a greater space in some other brain regions 82, 83.
Rats perfused to remove blood 4 h after intravenous injection of gold glyconanoparticles
had only ~4% as much ENM in their brain as rats that had not been perfused 84.
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Similarly, perfusion reduced gold in three brain regions to 7 to 18% of that seen on nonperfused rats after intra-abdominal nanogold injection 85. These results, and the rapid
ENM decline over time in the whole brain or brain regions, e.g., 85-89, which are
interpreted as not reflecting parenchymal entry, and the decrease in ENM in brain
capillaries but not parenchyma over 24 hours 90, suggest many studies that reported
brain ENM in the absence of removal of blood in the brain significantly over-estimated
the amount of ENM that entered brain parenchyma. Some studies accounted for the
contribution of blood to brain ENM 23, 83, 91, however this does not fully remove the
contribution of ENM in sites other than brain parenchyma, such as adsorption to the
luminal wall of brain vasculature and ENM presence in cellular and membrane
components of the BBB 41, 92. In several studies differences seen in short-term time
points did not persist to later times. None of these studies verified ENM distribution into
brain parenchyma. These results suggest that not all of the ENM penetrated into brain
parenchyma, but that the temporal difference might be due to ENM in blood within the
brain or adherent to the luminal wall of brain vasculature that subsequently distributed
away from these sites 93-98. A few reports verified ENM brain parenchyma entry 99, 100,
but one cannot conclude from one of these 99 that size influenced brain levels of gold
because this ENM was given by intraperitoneal injection. The difference in brain gold
ENM could be due to differences in uptake from the peritoneal cavity. Because the
distinction between ENM in the brain vs. brain parenchyma has seldom been made,
reports that claimed brain ENM entry were assessed for evidence that the ENM entered
brain parenchyma. The findings are noted in Table S3.
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As noted above, it is difficult to isolate surface charge without confounding factors from
other variables. Several studies, although all from the same group, found less
distribution through brain for negative than near neutral ENMs when introduced into ex
vivo brain 72, 101. In vivo results addressing the relationship between surface charge and
brain association are not consistent, preventing a conclusion 102-106. A large number of
studies showed evidence that surface coating affected brain association, reflecting the
extensive efforts to overcome the restrictions to brain entry presented by the BBB. No
attempt was made to relate results from in vitro studies of brain-derived cells (Table S1)
to the in vivo situation (Table S3) due to the great restriction of the BBB to brain entry.

IX. In vivo studies describing how ENM physicochemical properties affect their
pharmacodynamic responses (effects/organism responses)
Table S4 contains summaries of reports of studies that determined response/effect
endpoints in the mouse, rat, guinea pig, and rabbit NS of more than one ENM. One
would expect greater response when a greater amount of ENM associates with the
brain. This was seen in a study that determined both endpoints 107. Smaller ENMs
produced greater responses than larger ENMs 99, 108, 109 but a firm conclusion that size
correlates with NS response is prevented by the entanglement of their physicochemical
properties. Although ENM size affects its NS response, the relationship is not as simple
as its influence on brain association. No studies investigating the influence of size were
identified using ENM intravenous administration to the studied animal where more than
one ENM was investigated. Uptake from the exposure site (oral, intraperitoneal,
intranasal) may influence the NS response, preventing attribution of NS response to
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size when these routes were employed. Only one study employing the intravenous
route suggests cationic surface charge was associated with greater response, as might
be predicted by neutralization of the negative charge on the BBB 102. A firm conclusion
that surface charge correlates with NS response is again prevented by the
entanglement of their physicochemical properties.

X. The ENMs that have been studied for their physicochemical properties that
influence pharmacokinetic and/or pharmacodynamic interaction with the
nervous system
A minority of the studies cited in the Supporting Materials investigated polymer-based
ENMs, primarily focused on targeting or permeating the blood-brain barrier, entering the
brain, or targeting cancer or cancel cells. The polymer-based studies were generally
published sooner (median 2007, range 1990 to 2015) than the metal- and carbon-based
ENM studies (median 2012, range 2001 to 2016). A contributor to the difference may be
the concern about adverse and persistent effects of the generally insoluble carbon-,
silica-, metal-, and metal oxide-based ENMs.

XI. Conclusions
It is well established that ENM physicochemical properties can affect their
pharmacokinetics (uptake, distribution, and persistence) and resulting responses. This
has been demonstrated in organ systems other than the NS, evidenced by the
extensive clearance of ENMs into the liver and spleen, and ENM modifications that
reduce this to target other sites. It has been less well demonstrated for the NS and not
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previously reviewed. Of the ENM physicochemical properties that have been
investigated for their influence on NS distribution and effects (chemical composition,
size, shape, surface charge, and surface coating) the greatest emphasis has been on
surface coating, particularly studies attempting to preferentially target ENM delivery to,
and effects on, the brain. Studies with stem cells, blood-brain barrier cells, neurons and
neuron-like cells, and tumor cells, as well as whole animals, have shown the influence
of ENM surface coating on distribution and effects. Size has been shown to influence
ENM distribution, as an inverse relationship for distribution across in vitro BBB models,
into the brain of whole animals, and effect on neurons and neuron-like cells; and greater
tumor cell association or uptake of 40 to 50 nm ENMs than larger or smaller ones.
Strong evidence for the influence of chemical composition, shape, and surface charge
on NS pharmacokinetics and effects is generally lacking.
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